Flat colorectal tumors, characterized by high-grade dysplasia from early small flat mucosal lesions, exhibit a relatively aggressive clinical behavior and are known for their infrequent K-ras mutations. In this study, we investigated the methylation status of the RASSF1A promoter in association with 3p LOH and K-ras mutations in 48 flat colorectal tumors (39 early carcinomas and nine intramucosal high-grade dysplasias). RASSF1A hypermethylation was detected in 39 of 48 (81.3%) tumors and RASSF1A methylation was also detected in 19 of 39 (49%) normal colonic mucosal tissues. 3p21.3 LOH was detected in 20 of 42 (47.6%) cases, but RASSF1 methylation was detected in cases with LOH (14 cases) and retention of 3p21.3 (20 cases). K-ras mutations were detected in seven of 48 (14.6%) tumors and the concordant occurrence of K-ras mutation and RASSF1A methylation was detected in three of 48 cases (6.3%). Overall, there was a statistically significant mutually exclusive relationship between K-ras mutations and RASSF1A methylation. In conclusion, promoter hypermethylation of RASSF1A is a frequent event and may start early in the background normal mucosa in this tumor type. An alternative cascade of abnormalities in RAS transduction pathways may be responsible for the flat morphology and aggressive nature of flat colorectal neoplasms.
Flat colorectal tumors, characterized by high-grade dysplasia from early small flat mucosal lesions, exhibit a relatively aggressive clinical behavior and are known for their infrequent K-ras mutations. In this study, we investigated the methylation status of the RASSF1A promoter in association with 3p LOH and K-ras mutations in 48 flat colorectal tumors (39 early carcinomas and nine intramucosal high-grade dysplasias). RASSF1A hypermethylation was detected in 39 of 48 (81.3%) tumors and RASSF1A methylation was also detected in 19 of 39 (49%) normal colonic mucosal tissues. 3p21.3 LOH was detected in 20 of 42 (47.6%) cases, but RASSF1 methylation was detected in cases with LOH (14 cases) and retention of 3p21.3 (20 cases). K-ras mutations were detected in seven of 48 (14.6%) tumors and the concordant occurrence of K-ras mutation and RASSF1A methylation was detected in three of 48 cases (6.3%). Overall, there was a statistically significant mutually exclusive relationship between K-ras mutations and RASSF1A methylation. In conclusion, promoter hypermethylation of RASSF1A is a frequent event and may start early in the background normal mucosa in this tumor type. An alternative cascade of abnormalities in RAS transduction pathways may be responsible for the flat morphology and aggressive nature of flat colorectal neoplasms.
Introduction
Classical forms of colorectal cancer are characterized by the initial appearance of exophytic adenoma with lowgrade dysplasia. The lesion is followed by progressive accumulation of genetic alterations in the adenoma with increasing dysplasia. The adenoma focus eventually leads to invasive cancer foci (Fenoglio and Lane, 1974; Morson, 1974; Vogelstein et al., 1988) . Although not common, distinct morphological patterns and clinicopathological profiles of flat-type colorectal neoplasm have been well characterized. They are often associated with high-grade dysplasia from the early small flat but not exophytic mucosal lesions, and exhibit a relatively aggressive clinical behavior with a tendency to invade deep mucosal layers with lymphovascular permeation over a short time course (Shimoda et al., 1989; Tada et al., 1994) . Since the early detection of such flat lesions is difficult compared with exophytic adenoma, they are often overlooked and tend to be found at a late stage of development. Genetic studies on flat colorectal tumors are scarce. The frequency of K-ras mutations is less than that of conventional sporadic colorectal tumors mostly derived from an exophytic adenoma-carcinoma sequence Minamoto et al., 1994; Olschwang et al., 1998) . Also, flat tumors frequently demonstrate early inactivation of p53 with concomitant allelic loss of 17p (Yukawa et al., 1994; Rubio and Rodensjo, 1996; Mueller et al., 1998) . Through microdissection and loss of heterozygosity (LOH) analysis, we identified patterns of genetic progression and/or divergence in these flat colorectal neoplastic foci, with some foci evolving into an invasive form (Fujii et al., 2002) . The occurrence of de novo type carcinogenesis with early and simultaneous LOH on multiple chromosomal loci has also been suggested (Mueller et al., 1998; Fujii et al., 2002) .
Recently, Dammann et al cloned and characterized the Ras association domain family 1 gene (RASSF1) from the tumor suppressor locus 3p21.3 (Dammann et al., 2000; Lerman and Minna, 2000; Burbee et al., 2001) , a region that frequently shows a loss of heterozygosity (LOH) in a variety of human cancers. RASSF1 has two major splice isoforms, RASSF1A and RASSF1C, which are derived from different promoters but are expressed in a variety of normal cells (Dammann et al., 2000) . RASSF1C may function in the Ras signaling pathway. It binds to Ras in a GTP-dependent manner and its overexpression induces apoptosis (Vos et al., 2000) . RASSF1A regulates a proapoptotic pathway through heterodimerization with the Ras effector NORE1, and interacts with proapoptotic protein kinase MST1, which mediates the apoptotic effect of RAS (Khokhlatchev et al., 2002) . Also, this gene may play a role in the suppression of cell cycle progression by inhibiting cyclin D accumulation (Shivakumar et al., 2002) . Re-expression of RASSF1A in cancer cells reduces colony formation, suppresses anchorage-independent growth and inhibits tumor formation in nude mice. These activities support the role for RASSF1A as a tumor suppressor gene (Dammann et al., 2000) . Somatic mutational inactivation is rare in this gene (Dammann et al., 2000 (Dammann et al., , 2003b Agathanggelou et al., 2001; Burbee et al., 2001; Lo et al., 2001) . However, epigenetic inactivation of RASSF1A by hypermethylation of the promoter region has been described for a variety of human carcinomas including lung, breast, kidney, prostate, ovary, melanoma, gastric and nasopharyngeal carcinoma (Dammann et al., 2000 Lerman and Minna, 2000; Agathanggelou et al., 2001; Byun et al., 2001; Lo et al., 2001; Yoon et al., 2001; Liu et al., 2002; Spugnardi et al., 2003) . In addition, it is considered to be one of the most commonly methylated genes in human cancer. However, in colon cancer, the methylation of RASSF1A is not a frequent event and 45 of 222 (20%) conventional colorectal cancers have been shown to be methylated. Furthermore, RASSF1A hypermethylation and K-ras activation are mutually exclusive events in the development of colorectal carcinomas (van Engeland et al., 2002) . Similarly, an inverse relationship between RASSF1A hypermethylation and K-ras mutation has been reported in pancreatic cancer as well (Dammann et al., 2003a) .
As a result of the low frequency of K-ras mutations, and the occurrence of 3p LOH in a subset of flat-type colorectal tumors (Yashiro et al., 2001; Fujii et al., 2002) , we hypothesized that different modes of Ras signaling abnormalities such as the involvement of RASSF1A alteration may exist in this aggressive morphological variant of colorectal tumor. In the present study, we investigated the methylation status of RASSF1A, together with K-ras mutations, and LOH at 3p loci in 48 cases of early flat colorectal tumor. We show that RASSF1A methylation is a frequent event and may start in normal mucosa.
Results

LOH at 3p
3p LOH was detected homogeneously throughout all microdissected foci or only in some foci microdissected (heterogeneous LOH) for each case. In all, 24 cases (52.2%) showed LOH in one or more microsatellite markers on 3p. Of these cases, 18 (78.3%) showed homogeneous LOH and the remaining six showed heterogeneous LOH. Two cases showed microsatellite instability for the majority of the 3p markers analysed. These tumors also showed microsatellite instability in three of five (FL57) and four of five (FL59) foci for D2S123, D5S346, BAT25, BAT26 and D17S250. When LOH was scored for each chromosomal locus, markers at 3p21.3 (the locus of RASSF1A) showed LOH in 20 of 42 informative cases (47.6%), with 35.7% showing homogeneous LOH throughout microdissected foci. LOH frequencies for the chromosomal foci (homogeneous/heterogeneous) are summarized in Tables 1 and 2 . Representative histology of these cases and gels showing homogenous LOH are shown in Figure 1 .
Methylation of RASSF1A
We used the MSP approach to evaluate the methylation status of the RASSF1A promoter in flat colorectal tumors and corresponding matched morphologically normal colorectal mucosal tissue from cancer patients. Hypermethylation of the RASSF1A promoter CpG region was detected in 39 of 48 cases (81.3%). The remaining nine cases (18.8%) showed only PCR bands for unmethylated primers. MSP for unmethylated bands was detected for all cases. These unmethylated bands may be due to DNA contamination from normal cells and/or unmethylated alleles or cells in the tumor cell population. Next, we analysed matched morphologically normal mucosal tissue adjacent to tumors from the patients with flat-type colorectal tumor. Of 39 RASS-F1A methylated tumors, 19 (49%) showed RASSF1A methylation of the matched morphologically normal mucosa as well. On the other hand, zero of nine of the matched morphologically normal mucosa from RASS-F1A unmethylated tumors exhibited RASSF1A methylation. Representative examples of RASSF1A MSP reactions of 14 flat-type colorectal tumors and RASS-F1A MSP reactions for matched tumor portions and morphologically normal colorectal epithelium from eight patients are shown in Figure 2 .
K-ras mutation
To investigate the alteration of Ras in flat colorectal tumors, we screened mutations of exon 1 (which includes codons 12 and 13), and exon 2 (which includes codons 59, 61 and 63) of the K-ras gene using SSCP. Mutations were confirmed by direct sequence analysis. K-ras codon 12 was mutated in seven of 48 (14.6%) tumors, and three tumors (case FL15, FL45 and FL83) showed mutation from wild-type GGT (Gly) to GAT (Asp). Tumor FL71 and FL86 showed a mutation from GGT (Gly) to GTT (Val), FL72 showed mutation from GGT (Gly) to GCT (Ala), and FL99 had mutated from GGT (Gly) to TGT (Cys). No mutations in K-ras codons 13, 59, 61 and 63 were detected. Representative examples of the mutation analysis of codon 12 and 13 of the K-ras gene in flat-type colorectal tumor are shown in Figure 3 .
RASSF1A methylation, 3p21 LOH and K-ras mutaion
RASSF1A methylation and allelic loss at 3p21.3. is a major mechanism responsible for suppression of RASS-F1A gene function. Furthermore, a mutually exclusive RASSF1A methylation in flat-type colorectal tumor N Sakamoto et al relationship between RASSF1A methylation and K-ras mutation has been reported. Thus, we analysed the association between RASSF1A methylation status and K-ras mutations (Table 3) , and the association between RASSF1A methylational status and 3p21 LOH (Table 4) . K-ras mutations were frequently observed in RASSF1A unmethylated flat-type colorectal tumors (four out of nine ¼ 44.4%) compared to RASSF1A methylated samples (three of 39 ¼ 7.69%) (P ¼ 0.017). Conversely, RASSF1A methylation was detected in 36 out of 41 cases (88%) without K-ras mutations and three of seven cases (43%) with K-ras mutations (P ¼ 0.017). Only three of 48 cases (6.3%) possessed RASSF1A methylation and K-ras mutations. As shown in Table 4 , concomitant hypermethylation of RASSF1A and 3p21.3 LOH was detected in 14 of 42 informative cases (33%). Out of 20 tumors with 3p21.3 LOH, 14 (70%) showed hypermethylation of RASS-F1A, and 20 of 22 tumors (90%) with retention of 3p 21.3 showed hypermethylation of RASSF1A. However, no correlation was found between 3p21.3 LOH and RASSF1A methylation (P>0.05). Conversely, 14 of 34 informative cases (41%) with hypermethylation of RASSF1A showed LOH at 3p21.3, and six of eight cases (75%) without methylation of the gene showed 3p21.3 LOH (P>0.05).
Discussion
In this study, we found frequent methylation of RASSF1A (81.3%) in early flat colorectal tumors, which show low rates of K-ras mutations but early LOH of 3p21.3. The RASSF1A isoform is epigenetically inactivated in carcinomas of lung (small-cell lung cancer 72-79%, non-small-cell lung cancer, 30-38%), breast (49-62%), kidney (56-91%), prostate (53-100%), thyroid (71%) and several other carcinomas (Dammann et al., 2003b) . The frequency of methylation of RASSF1A is dependent on organs and the type of tumor (histopathologic type) even if it occurs in the same organ (subtypes of cancers in the lung , pancreas (Dammann et al., 2003a) and kidney (Morrissey et al., 2001) ). In sporadic colorectal cancers, the frequency of methylation of the CpG island promoter region found in RASSF1A is relatively lower (12-45%) than for other solid tumors with low rates of K-ras mutations (Yoon et al., 2001; van Engeland et al., 2002; Wagner et al., 2002) . Since K-ras and RASSF1A gene products function in the same signaling pathways, a mutually exclusive association of K-ras mutations and RASSF1A hypermethylation has been described for several types of cancers. In a study of 222 sporadic colorectal cancers (most were assumed to be derived from a common exophytic adenoma-carcinoma sequence), van Engeland et al. found K-ras mutation in 39% of the colorectal cancers, whereas 20% of the cases possessed RASSF1A methylation. Only 5% (11 of 222) cases showed K-ras mutations and RASSF1A methylation (van Engeland et al., 2002) . Similarly, an inverse correlation between RASSF1A silencing and K-ras activation is present in pancreatic cancer (Dammann et al., 2003a) . Flat-type colorectal cancer has a low frequency of K-ras mutations, and we detected K-ras mutations in only seven of 48 (14.6%) cases, which is similar to previous reports Minamoto et al., 1994; Olschwang et al., 1998) . On the other hand, the frequency of RASSF1A methylation (81.3%) was among the highest among tumors previously analysed. In the early flat colorectal tumors examined in the present study, we found a statistically significant inverse relationship between the alteration of the two genes. The rare occurrence of simultaneous alterations of two genes within the same signaling pathway has been observed for b-catenin/APC (Sparks et al., 1998) and Rb/P16
INK4a (Serrano, 1997) . Thus, a similar situation may apply to the alteration of the RAS signaling cascade in flat-type colorectal tumors.
In the present and previous works, LOH of 3p was found to be relatively frequent in flat-type colorectal tumors, similar to a previous study (Yashiro et al., 2001) . We observed 18 cases (37.5%) showing 3p LOH homogeneously throughout multiple microdissected foci, indicating that 3p LOH occurred early during carcinogenesis in these cases. Many of the present cases with allelic loss at 3p21.3, the locus for RASSF1A, showed large areas of deletion on 3p, indicating the possible involvement of one or more TSGs in this region in flat colorectal tumors. Multiple tumor suppressor genes or related genes are located on 3p, namely VHL (3p25-26), TGFBR2 (3p22), RASSF1A (3p21.3), MLH1 (3p21.3), b-catenin (3p21) and FHIT (3p12-14.2). Alterations in these genes or others may also be involved in the development of flat-type colorectal cancer. When methylation of RASSF1A is accompanied by 3p21.3 LOH, the gene is considered to satisfy Knudson's twohit mechanisms for inactivation of the gene. We found that 14 of 20 tumors (70%) with 3p21 LOH possessed RASSF1A methylation, indicating RASSF1A as a possible TSG in these cases. However, we also observed (Wagner et al., 2002) , papillary (chromophilic) renal carcinomas (44% methylation) (Morrissey et al., 2001) , medulloblastoma (79% methylation) (Lusher et al., 2002) and malignant melanoma (41% methylation) (Spugnardi et al., 2003) . These cases may exhibit biallelic methylation of the gene without a deletion of the other allele. Thus, in the present study, cases involving a discordant association of RASSF1A and 3p LOH may be explained by: biallelic methylation of RASSF1A, involvement or association with other TSGs on 3p and haploinsufficiency of RASSF1A (Celeste et al., 2003) . In colonic carcinogenesis, among a number of genetic alterations, K-ras mutation at codon 12 is significantly associated with predominantly polypoid growth (Chiang et al., 1998) . Although K-ras mutations and RASSF1A are involved in the same signaling pathway, their interaction with other factors, and hence their global effect, may be significantly different. Whether an abnormality in RASSF1A is a critical morphological determinant of the flat growth pattern or whether a lack of K-ras mutations causes nonpolypoid growth is undetermined and should be examined in future studies.
Hypermethylation of RASSF1A is associated with patient survival rate in non-small-cell lung cancer, and bladder cancer (Burbee et al., 2001; Maruyama et al., 2001) . Aggressive tumors are frequently associated with RASSF1A methylation in cancers of the thyroid and prostate Schagdarsurengin et al., 2002) . Despite their small size, early flat colorectal tumors progress relatively quickly into deeply invasive tumors which frequently permeate the lymphatics and veins (Shimoda et al., 1989; Tada et al., 1994) . Thus, a frequent RASSF1A methylation even in the early-stage tumor cases in our present study may be partly responsible for the aggressive clinical course associated with flat colorectal tumors.
A number of genes, including those encoding the estrogen receptor, MyoD1, CSPG2 (Versican), insulinlike growth factor 2 (IGF2), N33 and PAX6, show methylation in normal colonic mucosa as a function of age. Also, TSGs such as p16 on 9p21 are hypermethylated in normal mucosa as well as dysplastic mucosa in patients with ulcerative colitis (UC), a condition associated with an increased risk of colon cancer (Issa et al., 2001) . Thus, the methylation status of certain genes is accelerated in normal tissue as a field defect under predisposing conditions such as chronic inflammation or a preneoplastic microenvironment. In 19 of 39 cases (48.7%) with RASSF1A methylation in the tumor portions, we detected the methylation of the RASSF1A gene in matched normal colorectal mucosal tissue, which was histologically normal without any adenomatous or dysplastic changes and without the presence of an inflammatory background. Methylation of RASSF1A in normal tissue is rare , but is different depending on tissue origin, cell type and nonphysiological conditions. Normal lymphocytes and the skin are not methylated (Lehmann et al., 2002) . Methylation in nontumor portions has been detected in 4% of esophageal squamous mucosa in patients with squamous cell carcinoma (Kuroki et al., 2003) . In all, 44% of chronic pancreatitis tissues possess RASSF1A methylation (Dammann et al., 2003a) . In breast tissue, RASSF1A is frequently methylated in benign proliferative lesions and benign papilloma. However, normal breast tissue is never methylated (Lehmann et al., 2002) . Hepatocellular carcinoma shows frequent methylation of RASSF1A (93%). Methylation also occurs in liver fibrosis (two of two cases) and in liver cirrhosis (three of four cases), both of which are predisposing conditions for hepatocellular carcinoma (Schagdarsurengin et al., 2003) . In normal colonic mucosa, Engeland et al. detected no methylation from six noncancer patients. They detected methylation in only one of seven normal colonic tissue DNA samples from colon cancer patients (van Engeland et al., 2002) . A somewhat higher proportion of RASSF1A methylation in normal colonic mucosa was reported by Wagner et al. In all, 45% (13 of 29) of primary colorectal cancers are methylated, and four of 11 (36%) match the morphologically normal mucosa from cancer patients (Wagner et al., 2002) . Our finding of 49% methylation in normal counterpart mucosal tissue in flat colorectal cancer patients is one of the highest frequency to be reported thus far. Although histologically normal in appearance, background colonic mucosa in the cases with flat colorectal tumors may be aged or damaged (field effect). Whether methylation of RASSF1A is related to aging or damaged tissue is unknown. If this is the case, we believe that flat colorectal tumors may arise from a relatively injured mucosal background (but without an inflammatory background such as for ulcerative colitis) with early involvement of RASSF1A methylation and p53 overexpression and a relative lack of K-ras mutations. The early occurrence of RASSF1A methylation may exclude the necessity of K-ras activation to cause alterations in the Ras-signaling pathway, thereby avoiding an exophytic configuration but inducing a predominantly flat-type neoplastic process.
In conclusion, promoter hypermethylation of RASS-F1A is a frequent event in early flat-type colorectal tumors which exhibit infrequent K-ras mutations and early 3p21.3 LOH. Hypermethylation of the RASSF1A gene may start early in the background of nonneoplastic colorectal mucosa. Thus, an alternative cascade of abnormalities in the RAS-signal transduction pathway may be involved from an early stage in this morphologically unique and aggressive variant of colorectal tumor.
Materials and methods
Patients and tissues
Paraffin-embedded archival pathology blocks of flat colorectal tumors were obtained from the Pathology Department at . These cases were initially tested for the quality of DNA presentation for adequate and reproducible polymerase chain reaction (PCR) amplification. In total, 48 cases were submitted for the present genetic analysis consisting of 42 males and six females. The patient age ranged from 44 to 88 years, with a mean age of 63.7. The tumor was located in the colon in 29 cases, and in the rectum in 19 cases. The size of the tumor ranged from 4 Â 4 to 45 Â 25 mm with an average width of 11.8 mm. A lesion was defined as flat when the dysplastic mucosal thickness was less than twice the thickness of adjacent non-neoplastic mucosa. Since histopathological terminology for intramucosal neoplastic lesions is different between Japanese and Western pathologists, and the term 'intramucosal carcinoma' commonly used in Japan is not widely used in the Western, we have used the term 'high-grade dysplasia (HGD)' for intramucosal highly dysplastic lesions. Tumors with submucosal invasive foci were considered definite for invasive carcinoma. When low-grade flat dysplasia was detected, we classified them as flat adenomas. Nine of the tumors showed HGD without submucosal invasion. The remaining 39 cases showed focal submucosal invasion, indicating that they were unequivocal invasive cancers. No tumors showed invasion to or deeper than the muscularis propria. Submucosal invasion was graded from sm1 (shallow) to sm3 (deep and close to the muscularis propria). None of the tumors were low-grade flat adenomas. Table 1 summarizes the clinicopathological profiles, together with the results of the genetic analysis.
Microdissection
Serial 8 mm sections were cut, deparaffinized and stained with hematoxylin and eosin (H&E). Portions of the tumor were microdissected using a 27-gauge needle under an inverted microscope. A laser-assisted microdissection system (Leica Laser Microdissection Systems, Leica Microsystems, Wetzlar, Germany) was also used. At least 95% of the microdissected cells were tumor cells. These highly purified samples aided the subsequent detection of allelic losses without contamination by normal DNA. For each case, two to seven foci were selected. A total of 182 tumor foci were microdissected from 48 cases. Normal stromal and inflammatory cells were separately collected and used as normal control DNA for the LOH analysis. Matched morphologically normal mucosal tissue from cancer patients was also microdissected for the methylation study. Microdissected tissue was digested overnight at 531C in buffer containing 0.5% NP40, 50 mM Tris-HCl (pH 8.0), 1 mM EDTA and 200 mg/ml proteinase K. The lysate was heated at 951C for 10 min, and stored at À201C until used for PCR. Tissues were separately extracted and stored for subsequent bisulfite treatment-MSP analysis.
LOH
The following microsatellite markers were used: 3p12 (D3S1261, D3S3681), 3p14.2. (D3S1234, D3S1285, D3S1300), 3p21.3 (D3S1568, D3S1581, D3S3624, D3S3678) and 3p25 (D3S1307, D3S1560). Chromosomal regions for each marker were derived from a cytogenetic/genetic database. D2S123, D5S346, BAT25, BAT26 and D17S250 were also used for the identification of microsatellite instability (MSI). Markers D3S1234, D3S1286, D3S1293, D2S123, D5S346, BAT25, BAT26 and D17S250 were purchased from Research Genetics (Research Genetics, Co. Ltd, Huntsville, AL, USA). All other primers were designed in our laboratory, and the sequences are available upon request. PCR reactions contained 1 ml of DNA, 0.4 mM of m[ 32 P]ATP-radiolabeled primers, 0.2 mM of deoxyribonucleoside triphosphate, 10 mM TrisHCl (pH 8.3), 1.5 mM MgCl 2 , 50 mM KCl and 0.4 U Taq polymerase in a reaction volume of 10 ml. The PCR products were run on 5% denaturing polyacrylamide-urea-formamide gels, and LOH was detected using a Phosphoimage Analyzer (Bas 2500, Bio Imaging System, Fuji Film, Tokyo, Japan).
Methylation
The methylation status in the promoter region of RASSF1A was determined by MSP as described previously (Herman et al., 1996) . Briefly, DNA was bisulfite-treated to convert unmethylated cytosines into uracils. Subsequent MSP was used to distinguish methylated alleles of a given gene based on DNA sequence alterations after bisulfite treatment. MSP primers used for nested PCR amplification of methylated and unmethylated sequences and PCR conditions were described previously (van Engeland et al., 2002) . The primers for the first PCR reaction were 5 0 -GTT TAG TTT GGA TTT TGG GGG AG-3 0 (sense primer) and 5 0 -CCC RCA ACT CAA TAA ACT CAA ACT C-3 0 (antisense primer), and primer sequences for the unmethylated reaction were 5 0 -GGG GTT TGT TTT GTG GTT TTG TTT-3 0 (sense primer) and 5 0 -AAC ATA ACC CAA TTA AAC CCA TAC TTC A-3 0 (antisense primer). Primer sequences for the methylated reaction were 5 0 -GGG TTC GTT TTG TGG TTT CGT TC-3 0 (sense primer) and 5 0 -TAA CCC GAT TAA ACC CGT ACT TCG-3 0 (antisense primer). All PCR reactions were performed with controls for unmethylated RASSF1A alleles (DNA from normal lymphocytes), methylated RASSF1A alleles (RASSF1A methylated breast tumours) and a negative control without DNA. PCR products were separated on 18% nondenaturing polyacrylamide gel, stained with ethidium bromide and visualized under UV illumination. MSP-PCR for all samples was repeated at least three times to confirm their unmethylation/methylation status.
K-ras mutation
Mutations in the K-ras exons were initially screened by singlestrand conformational polymorphim (SSCP) analysis using MDE TM gels according to the manufacturer's instructions (Mutation Detection Enhancement Gel, BMA, Inc.). Intronic primers were designed on the basis of intron-exon boundaries to amplify exons 1 and 2. The sequences of primers used for the amplification of exon 1 of K-ras, which contains codons 12 and 13, were: 5 0 -ATAAGGCCTGCTGAAAATGA-3 0 (forward), 5 0 -GGTCCTGCACCAGTAATATGC-3 0 (reverse), 5 0 -AAAAGGTACTGGTGGAGTATTTGA-3 0 (forward) and 5 0 -TGATTCTGAATTAGCTGTATCGTC-3 0 (reverse). The sequences for primers used for the amplification of exon 2 of K-ras, which contains codon 61, were: 5 0 -TGTGTTTCTCCCT TCTCAGGA-3 0 (forward) and 5 0 -TGGCAAATACACAAAG AAAGC-3 0 (reverse). For the SSCP analysis, PCR was performed as described for the LOH analysis using radioisotope-labeled primers. Samples with aberrant bands on SSCP gels were further confirmed by direct sequencing analysis using an ABI 377 automated sequencer with an ABI PRISM Big Dye Terminator Cycle Sequencing Kit (Applied RASSF1A methylation in flat-type colorectal tumor N Sakamoto et al Biosystems, Foster City, CA, USA). The same primers for the SSCP analysis were used for the direct sequencing reaction.
Statistical analysis
The association between methylation status of RASSF1A, allelic loss of 3p and K-ras mutation was analysed using a w 2 test and Fisher's exact test. Po0.05 was regarded as statistically significant.
Abbreviations RASSF1A, Ras association domain family 1 gene A; LOH, loss of heterozygosity; MSP, methylation-specific PCR; SSCP, single-strand conformation polymorphism.
